Basilea Pharmaceutica Ltd. Logo
 

Anti-Infectives 2005

 
 
 
  • Amsler KM, Bush K, Wira E, Foleno B. In vitro susceptibility of ceftobiprole against non-fermenting clinical isolates. 45th ICAAC 2005. Poster E-313.
  • Appelbaum PC, Smith K. MIC values of ceftobiprole and comparators towards Horaxella catarrhalis. 45th ICAAC 2005. Poster E-304.
  • Appelbaum PC and Jacobs MR. Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria. Curr Opin Microbiol 2005; 8:510-7
  • Barrow EW, Dreier J. Selective inhibitors for anthrax. 45th ICAAC 2005. Poster F-2072.
  • Appelbaum PC, Bogdanovich T, Staphylococcal single-step resistance selection studies with ceftobiprole and comparators. 45th ICAAC 2005. Slide presentation F-1163.
  • Bogdanovich T, Ednie LM, Shapiro S, and Appelbaum PC. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 2005; 49:4210-19.
  • Breuker I., Meis J. F., Verweij P. E., Mouton J. W.; In vitro activity of the new azole BAL4815 against clinical dermatophyte isolates. 45th ICAAC 2005. Poster  M-1622.
  • Breuker I., Meis J. F., Verweij P. E., Mouton J. W.; In vitro activity of the new azole BAL4815 against clinical Candida isolates comprising resistant C. albicans and less susceptible Candida spp. 45th ICAAC 2005. Poster M-1621.
  • Chambers HF; Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49:884-8
  • Clark C, Bogdanovich T, Ednie LM, Appelbaum PC. Low propensity of ceftobiprole to select for resistant mutants of H. influenzae and M. catarrhalis. 45th ICAAC 2005. Poster E-316.
  • Davies TA, Bush K. Activity of ceftobiprole and other b-lactams against Streptococcus pneumoniae U.S. clinical isolates with defined substitutions in penicillin-binding proteins (PBP) PBP1a, PBP2b, and PBP2x. 45th ICAAC 2005. Poster E-310.
  • Denis O, Deplano A, Nonhoff C, De Ryck R, Rottiers S, Struelens MJ. Ceftobiprole activity against epidemic strains of methicillin-resistant Staphylococcus aureus from hospitalized patients in Belgium. 15th ECCMID 2005.
  • Dreier J, Amantea EB, Gebhardt K, Nuoffer C, Wind M, Page MGP. A non-radioactive high-throughput screening assay to identify RNA polymerase inhibitors. 105th ASM General Meeting 2005
  • Ednie LM, Appelbaum PC. Antistaphylococcal kill kinetics of ceftobiprole and comparators. 45th ICAAC 2005. Poster E-306.
  • Ghannoum MA, Isham N. Antifungal activity of BAL4815, a novel azole against dermatophytes and emerging non-dermatophyte fungi including zygomycetes. 45thICAAC 2005. Poster M-1623.
  • Heep M, Geier C, Hofer B, Dantier C, Page MGP. Induction of ampC b-lactamases in Enterobacter cloacae triggers resistance to extended spectrum cephalosporins, but not to cefeprime and ceftobiprole. 45th ICAAC 2005. Poster E-308.
  • Heep M, Sahm DF, Draghi DC, Jones ME. Activity of ceftobiprole against recent clinical isolates of enterobacteriaceae from respiratory infections from hospitalized patients in Europe and USA. 15th ECCMID 2005.
  • Heep M, Sahm DF, Draghi DC, Jones ME. In-vitro activity of ceftobiprole against recent clinical isolates of Pseudomonas aeruginosa from hospitalized patients in Europe and USA. 15th ECCMID 2005.
  • Hujer AM, Kania M, Gerken T, Anderson VE, Buynak JD, Ge X, Caspers P, Page MGP, Rice LB. Structure-activity relationships of different beta-lactam antibiotics against a soluble form of Enterococcus faecium PBP5, a type II bacterial transpeptidase. Antimicrob Agents Chemother. 2005; 49(2): 612-8.
  • Jones RN, Sader HS, Fritsche TR. In vitro susceptibility testing guidelines for ceftobiprole (BAL9141) using CLSI disk diffusion and broth microdilution MIC methods. 45th ICAAC 2005. Poster D-1647.
  • Jones ME, Draghi D, Heep M, Flamm RK, Thornsberry C, Sahm DF. Ceftobiprole (BAL9141), an investigational cephalosporin with activity against MRSA, demonstrates in-vitro activity against clinical isolates of Pseudomonas aeruginosa. 43th IDSA 2005 (506).
  • Kosowska K, Hoellman DB, Lin G, Clark C, Credito K, McGhee P, Dewasse B, Bozdogan B, Shapiro S, Appelbaum PC. Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin. Antimicrob. Agents Chemother. 2005; 49(5): 1932-42.
  • Kresken M, Heep M. In vitro activity of ceftobiprole (BAL9141) in combination with ciprofloxacin, levofloxacin, amikacin, and tobramycin against clinical isolates of Pseudomonas aeruginosa. 45th ICAAC 2005. Poster E-311.
  • Lodise TP, Drusano GL, MA, L, Pypstra R, Kahn J, Noel GJ. Determination of optimal renal dosage adjustment for ceftobiprole (BPR). 43th IDSA 2005 (527).
  • Mouton JW, Verwij PE, Warn P, Denning D, Heep M, Isham N, Ghannoum M. In vitro activity of a new triazole BAL4815 against Candida isolates with decreased fluconazole susceptibility. TIMM 2005, Berlin, Poster P-021.
  • Page MGP, Caspers P, Kania M. Interaction of ceftobiprole with a purified soluble form of Staphylococcus epidermis PBP2’. 45th ICAAC 2005. Slide presentation F-1157.
  • Page MGP, Heim J. Superbugs: Apocalypse now or the day after tomorrow?
    European Biopharmaceutical Review. 2005; Spring edition:40-45.
  • Page MGP, Walsh CT. Antimicrobials. Curr Opin Microbiol. 2005; 8(5): 495-7.
  • Pankuch G, Lin G, Appelbaum PC. Time-kill activities of ceftobiprole and eight other agents against H. influenzae and M. catarrhalis. 45th ICAAC 2005. Poster E-305.
  • Pohlmann J, Lampe T, Shimada M, Nell PG, Pernerstorfer J, Svenstrup N, Brunner NA, Schiffer G, Freiberg C. Pyrrolidinedione derivatives as antibacterial agents with a novel mode of action. Bioorg Med Chem Lett. 2005; 15(4): 1189-92.
  • Queenan AM, Bush K. Ceftobiprole: Effect on ampC b-lactamase induction and resistance frequency in Gram-negative bacteria. 45th ICAAC 2005. Poster C1-55.
  • Schmitt-Hoffmann A, Yin L, Calhoun J, Thomas J, Shapiro S, Spickermann J. Distribution of ceftobiprole in bone matrix and bone marrow in a rabbit MRSA osteomyelitis model. 45th ICAAC 2005. Poster B-2007.
  • Schmitt-Hoffmann A., Spickermann J. and Wind M. Metabolic profile of BAL8557 and BAL4815 in liver microsomes (rat, human, mouse, rabbit, dog, cynomolgus) and rat hepatocytes. TIMM 2005, Berlin, Poster No. P-028.
  • Shapiro S, Thenoz L, Heinisch L, Möllmann U. Activities of novel siderophoric b-lactams towards gram-negative bacteria. 45th ICAAC 2005. Poster F-156.
  • Vaudaux P, Gjinovci A, Bento M, Li D, Schrenzel J, and Lew DP. Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49:3789-93.
  • Viljoen JJ, Mitha I, Heep M, Ghannoum M. Efficacy, safety, and tolerability of three different dosing regimens of BAL8557 vs. fluconazole in a double-blind, randomized, multicenter trial for the treatment of esophageal candidiasis (EC) in immunocompromised adults. 45th ICAAC 2005. Late Breaker Poster LB2-32.
  • Von Eiff C, Friedrich AW, Becker K, Peters G. Antistaphylococcal activity of ceftobiprole (BAL9141). 45th ICAAC 2005. Poster E-314.
  • Von Eiff C, Friedrich AW, Becker K, and Peters G. Comparative in vitro activity of ceftobiprole against staphylococci displaying normal and small-colony variant phenotypes. Antimicrob Agents Chemother 2005; 49:4372-4.
  • Warn PA, Sharp A, Denning DW. In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp.
    J Antimicrob Chemother. 2005; Epub ahead of print
  • Warn PA, Mosquera J, Sharp A, Denning DW. In vivo efficacy of the triazole BAL8557 (BAL) compared to voriconazole (VOR), itraconazole (ITC) and caspofungin (CAS) by a new qPCR and  quantitative culture in neutropenic murine model of Aspergillus flavus. 45th  ICAAC 2005, Poster B-48.
  • Warn P, Denning D, Heep M, Isham N, Ghannoum M. In vitro activity of a new triazole BAL4815 against Candida isolates with decreased fluconazole susceptibility. 45th  ICAAC 2005, Poster M-1620.
  • Warn PA, Sharp A, Denning DW. Dose response curves and dose fractionation studies with BAL5887 in a murine model of disseminated candidiasis 45th ICAAC 2005, Poster B-47.
  • Yin LY, Calhoun JH, Thomas JK, Shapiro S, Schmitt-Hoffmann AH, Urwyler H. Efficacies of ceftobiprole medocaril (BDR-M), vancomycin (VAN) and linezolid (LZD) for treatment of methicillin-resistant staphylococcus aureus (MRSA) osteomyelitis: Studies with a rabbit model. 43th IDSA 2005.
 
Info